Evidence map›Paper›PMID 40685914›Full record

Observational studyCPT: pharmacometrics & systems pharmacology2025

Integrated Modeling of Digital-Motor and Clinician-Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases.

Alzahra Hamdan, Andreas Traschütz, Lukas Beichert, Xiaomei Chen, Cynthia Gagnon, Bart P van de Warrenburg, Filippo M Santorelli, Nazlı Başak, Giulia Coarelli, Rita Horvath and 7 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04297891 (Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04297891 unknown statusnot on this map

Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias

Typeobservational_patient_registrySponsorDr. Rebecca SchuleRan2020 to 2025Enrolled250ConditionsSpastic AtaxiaArmsClinical rating scale to measure Ataxia disease severity and progression, Clinical rating scale to measure spastic paraplegia disease severity and progression, Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), Next-Gen Sequencing (NGS)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alzahra HamdanPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0002-3102-2707
Andreas TraschützDivision Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-8165-5898
Lukas BeichertDivision Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0009-0000-9259-9230
Xiaomei ChenPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0002-0663-0532
Cynthia GagnonGroupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Québec, Canada.
Bart P van de WarrenburgDepartment of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.
Filippo M SantorelliIRCCS Stella Maris Foundation, Pisa, Italy.ORCID https://orcid.org/0000-0002-1359-9062
Nazlı BaşakSchool of Medicine, KUTTAM-NDAL, Koç University, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-6977-2517
Giulia CoarelliSorbonne Université, Institut du Cerveau - Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.ORCID https://orcid.org/0000-0002-7824-8343
Rita HorvathDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Stephan KlebeDepartment of Neurology, University Hospital Essen, Essen, Germany.
PROSPAX consortium
EVIDENCE‐RND consortium
Rebecca SchüleDivision Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Andrew C HookerPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2676-5912
Matthis SynofzikDivision Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-2280-7273
Mats O KarlssonPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-1258-8297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Robust and highly sensitive outcomes are crucial for small trials in rare diseases. Combining different outcome types might improve sensitivity to identify disease severity and progression, yet innovative methodologies are scarce. Here we develop an Item Response Theory framework that allows integrated modeling of both continuous and categorical outcomes (ccIRT). With degenerative ataxias, a group of rare neurological coordination diseases, as a showcase, we developed a ccIRT model integrating two ataxia outcome types: a clinician-reported outcome (Scale for the Assessment and Rating of Ataxia; SARA; categorical data) and digital-motor outcomes for gait and limb coordination (continuous data). The ccIRT model leveraged data from 331 assessments from a natural history study for spastic ataxias. The model describes SARA items and digital-motor outcomes data as functions of a common underlying ataxia severity construct, evaluating 9 gait and 17 limb coordination digital-motor measures for their ability to add to SARA in estimating individual ataxia severity levels. Based on our proposed workflow for assessing digital-motor outcomes in ccIRT models, the final model selected three digital gait and three limb coordination measures, reducing average uncertainty in ataxia severity estimates by 49% (10% SD) compared to the SARA-only IRT model. Trial simulations showed a 49% and 61% reduction in sample sizes needed to detect disease-modifying effects in two genotypes. Overall, our ccIRT framework for combining multiple outcome domains, even of different variable types, facilitates a more precise estimation of disease severity and a higher power, which is particularly relevant for rare diseases with inherently small and short trials. Trial Registration: ClinicalTrials.gov: NCT04297891.

Indexed as

AtaxiaNervous System DiseasesRare DiseasesGaitHumansSeverity of Illness Indexclinical outcome assessmentsdigital‐motor outcomesgenetic ataxiasItem Response Theoryrare neurological diseases

Identifiers

PMID40685914
PMCPMC12625125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.